EX-23.2 5 axsm-ex23_2.htm EX-23.2 EX-23.2

 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements on:

 

•
Form S-8 (No. 333-217002);
•
Form S-8 (No. 333-208579);
•
Form S-8 (No. 333-230296);
•
Form S-8 (No. 333-226824);
•
Form S-8 (No. 333-238174);
•
Form S-8 (No. 333-256019);
•
Form S-8 (No. 333-264621);
•
Form S-8 (No. 333-271741);
•
Form S-8 (No. 333-272891);
•
Form S-8 (No. 333-281249); and
•
Form S-3 (No. 333-268664).

 

of our report dated February 27, 2023, with respect to the consolidated financial statements of Axsome Therapeutics, Inc., included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2024.

 

/s/ Ernst & Young LLP

 

New York, New York

February 18, 2025